CD274 and non-small cell lung carcinoma: Checkpoint and PD-L1 inhibitors like pembrolizumab, atezolizumab, and durvalumab have been approved for first or second-line treatment of PD-L1 positive advanced cancers [e.g., NSCLC (2, 3, 15)], urothelial cancer (16), and triple-negative breast cancer (17).